Cargando…
Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial
BACKGROUND: Alzheimer’s disease (AD) is associated with metabolic abnormalities linked to critical elements of neurodegeneration. We recently administered combined metabolic activators (CMA) to the AD rat model and observed that CMA improves the AD-associated histological parameters in the animals....
Autores principales: | Yulug, Burak, Altay, Ozlem, Li, Xiangyu, Hanoglu, Lutfu, Cankaya, Seyda, Lam, Simon, Velioglu, Halil Aziz, Yang, Hong, Coskun, Ebru, Idil, Ezgi, Nogaylar, Rahim, Ozsimsek, Ahmet, Bayram, Cemil, Bolat, Ismail, Oner, Sena, Tozlu, Ozlem Ozdemir, Arslan, Mehmet Enes, Hacimuftuoglu, Ahmet, Yildirim, Serkan, Arif, Muhammad, Shoaie, Saeed, Zhang, Cheng, Nielsen, Jens, Turkez, Hasan, Borén, Jan, Uhlén, Mathias, Mardinoglu, Adil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879258/ https://www.ncbi.nlm.nih.gov/pubmed/36703196 http://dx.doi.org/10.1186/s40035-023-00336-2 |
Ejemplares similares
-
EGb 761 reduces Ca(2+) influx and apoptosis after pentylenetetrazole treatment in a neuroblastoma cell line
por: Ovey, Ishak Suat, et al.
Publicado: (2023) -
Assessment of the neuroprotective potential of d-cycloserine and l-serine in aluminum chloride-induced experimental models of Alzheimer’s disease: In vivo and in vitro studies
por: Tozlu, Özlem Özdemir, et al.
Publicado: (2022) -
Ellagic Acid and Its Metabolites as Potent and Selective Allosteric Inhibitors of Liver Pyruvate Kinase
por: Battisti, Umberto Maria, et al.
Publicado: (2023) -
Discovery of therapeutic agents targeting PKLR for NAFLD using drug repositioning
por: Zhang, Cheng, et al.
Publicado: (2022) -
Systems Biology Approaches to Decipher the Underlying Molecular Mechanisms of Glioblastoma Multiforme
por: Kaynar, Ali, et al.
Publicado: (2021)